The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

Out of the 43 analysts that now have coverage on HUL, 27 of them have maintained a 'Buy' rating on the stock, while 13 of ...

There is mild anticipation that as the Snake year slithers in, the local IPO markets will open up, and the STI will hit a new ...

Taking a more bearish stance, CLSA has downgraded HUL to an Underperform rating. The brokerage firm also has slashed its ...

SK Hynix Inc.’s shares slid after record quarterly results failed to impress investors grappling with stagnant smartphone ...

India's most valued company, Reliance Industries Ltd (RIL), reported a robust performance in the third quarter of the current ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

SK Hynix Inc.’s shares slid 4.7% after its record quarterly profit and modest capex plans failed to impress investors betting ...